Combination therapy before and after surgery for early liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of liver cancer).
- You must be in good physical condition (able to do light activities) and be considered able to have surgery.
- Your cancer must not have spread outside the liver.
- You cannot have had prior cancer treatment (except for a procedure to drain bile).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination—cisplatin, gemcitabine (standard chemotherapy), and rilvegostomig (an immunotherapy)—given before and after surgery for a specific type of liver cancer called intrahepatic cholangiocarcinoma. The goal is to reduce the chance of the cancer coming back after surgery.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.